Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07105020 | iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer | not yet recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER |
| 1 |
| Aug 10, 2026 |
| clinicaltrials |
| NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | not yet recruiting | Phase 1 / Phase 2 | 67 | CoRegen, Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07753356 | VALIDATION OF FUSION CEMEP SCORE FOR OMITTING SYSTEMATIC PROSTATE BIOPSY(FUSION-CEMEP) | not yet recruiting | — | 150 | Marcelo Ruben OlivaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07747493 | 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy(PSMA-FT) | not yet recruiting | N/A | 8 | University Health Network, TorontoOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07650448 | WATER IV PCa (AS Sub-study) | not yet recruiting | N/A | 333 | PROCEPT BioRoboticsINDUSTRY | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07737457 | MICRO-ultrasound Guided Prostate SBRT(MICRO-S) | not yet recruiting | N/A | 112 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07733440 | PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria(PROACT) | not yet recruiting | N/A | 89 | Ahmadu Bello UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07735273 | eMindExCare for Prostate Cancer Patients Undergoing Active Treatment(eMindExCare) | not yet recruiting | N/A | 60 | The University of Hong KongOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07730151 | Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. | not yet recruiting | Phase 2 | 200 | RenJi HospitalOTHER | 0 | Jul 28, 2026 | clinicaltrials |
| NCT07730580 | Study of XNW5004 Tablets in Advanced Prostate Cancer(XNW5004 Tablet) | not yet recruiting | Phase 2 | 242 | Evopoint Biosciences Inc.INDUSTRY | 0 | Jul 28, 2026 | clinicaltrials |
| NCT07727473 | Preoperative Semaglutide Prior to Radical Prostatectomy | not yet recruiting | Early Phase 1 | 20 | Banner HealthOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07723651 | [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) | not yet recruiting | Phase 2 | 75 | Washington University School of MedicineOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07724080 | Resistance Exercise, IL-7 and Immune Phenotypes in Prostate Cancer | not yet recruiting | N/A | 40 | University of BathOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07278362 | Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance | not yet recruiting | Phase 4 | 35 | University of MiamiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07697989 | Pluvicto Real-world Investigation in Survival in Metastatic CRPC(PRISM) | not yet recruiting | — | 1,085 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 22, 2026 | clinicaltrials |
| NCT07709338 | Targeted Biopsy, Rapid Pathology, and Immediate Surgery in USTC High-Risk Prostate Cancer: A Prospective Multicenter Study | not yet recruiting | N/A | 150 | Anhui Provincial HospitalOTHER_GOV | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07709403 | Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study | not yet recruiting | — | 20 | Peking University First HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07702864 | Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention(CHEF) | not yet recruiting | N/A | 40 | University of ArizonaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07690462 | Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery | not yet recruiting | — | 120 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07682584 | Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis | not yet recruiting | — | 200 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07655557 | Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer | not yet recruiting | N/A | 100 | NYU Langone HealthOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677566 | 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial(IUNU-PC-123) | not yet recruiting | Phase 4 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674121 | PROLONG (PRostateOLaparibONcombinationGcc) Study(PROLONG) | not yet recruiting | — | 75 | AstraZenecaINDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07478536 | Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)(CHAS3) | not yet recruiting | — | 350 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07656337 | Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness(IAPSMA) | not yet recruiting | N/A | 10 | Lithuanian University of Health SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07644910 | Nudging Preventive Screening Via Message Framing and Bundling | not yet recruiting | N/A | 235,000 | University of ChileOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07635108 | MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)(PINPOINT) | not yet recruiting | N/A | 48 | Odense University HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07644754 | Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases(RIALTO) | not yet recruiting | N/A | 27 | University Hospital TuebingenOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07441837 | Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients(TeLuNa) | not yet recruiting | Phase 2 | 60 | Ankara UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07535905 | Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients(REVIVE) | not yet recruiting | Phase 2 | 96 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | not yet recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07526545 | Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial(UPRISE) | not yet recruiting | N/A | 800 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635524 | A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT. | not yet recruiting | Phase 2 | 34 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 1 | 140 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631858 | Perspectives About Online Information | not yet recruiting | N/A | 3,200 | NYU Langone HealthOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 3 | 700 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07623460 | Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer(ZENITH) | not yet recruiting | Phase 2 | 30 | Stuthi PerimbetiOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07620717 | Early Diagnosis of PROstate CANcer for Black Men(PROCAN-B+) | not yet recruiting | N/A | 300 | University of SunderlandOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07045415 | The Effect of Pelvic Floor Muscle Exercises After Radical Prostatectomy | not yet recruiting | N/A | 10 | KTO Karatay UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07495293 | Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer | not yet recruiting | Phase 1 | 20 | Yonsei UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07598032 | Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression(iCCaRE) | not yet recruiting | Phase 3 | 200 | University of Ilorin Teaching HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06298838 | High-resolution Intra-operative PSMA PET-CT in Prostate Cancer | not yet recruiting | — | 10 | IRCCS San RaffaeleOTHER | 0 | May 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2026source: clinicaltrials